Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Urology. 2019 Mar 27;129:153–159. doi: 10.1016/j.urology.2019.03.018

Figure 1.

Figure 1

Receiver-operating analysis (ROC) curves for patients with prostate biopsy. Panel A: Univariable ROC curves for PSA, PSAD, PHI and PHID with prostate biopsy using non-fused (NFUS) sampling. AUC’s and 95% CI are PSA 0.61 (0.49 to 0.72), PSAD 0.64 (0.53 to 0.75), PHI 0.78 (0.67 to 0.88), and PHID 0.72 (0.60 to 0.83).

Panel B: Multi-variable ROC curves for base model (age, DRE and prior biopsy) alone or with the addition of PSA, PHI and PSA plus PHI for NFUS sampling. AUC’s and 95% CI are Base 0.65 (0.55 to 0.75), Base + PSA 0.72 (0.68 to 0.82), Base + PHI 0.79 (0.68 to 0.89), Base + PSA + PHI 0.79 (0.68 to 0.89).

Panel C: Univariable ROC curves for PSA, PSAD, PHI and PHID with prostate biopsy sampled using fused (FUS) sampling. AUC’s and 95% CI are PSA 0.50 (0.38 to 0.62), PSAD 0.72 (0.62 to 0.83), PHI 0.70 (0.59 to 0.81), and PHID 0.82 (0.73 to 0.91).

Panel D: Multi-variable curves for base model (age, DRE and prior biopsy) alone or with the addition of PSAD, PHID and PSAD plus PHID for FUS sampling. AUC’s and 95% CI are Base 0.62 (0.50 to 0.74), Base + PSAD 0.75 (0.64 to 0.85), Base + PHID 0.86 (0.78 to 0.94) and Base + PSAD + PHID 0.86 (0.78 to 0.94).